| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Article |
From the Institute of Pathology,*
and the Clinic for
Urology,
University Basel, Basel, Switzerland;
VYSIS Incorporated,
Downers Grove, Illinois;
and the Laboratory of Cancer Genetics,§
National Human Genome Research Institute, National Institutes of
Health, Bethesda, Maryland
Inactivation of tumor suppressor genes on chromosome 9p is considered a critical event in renal cell carcinoma pathogenesis. Alterations of CDKN2A on 9p21 have been reported in renal cancer cell lines, but their relevance for primary renal carcinomas is unclear. Loss of heterozygosity (LOH) was analyzed by using four polymorphic microsatellites at D9S970 (9p12-9p13), D9S171 (9p13), D9S1748 (9p21), and D9S156 (9p21) in 113 primary conventional clear-cell renal cell carcinomas (CRCCs). Allelic deletion was detected in 21 of 88 informative CRCCs (24%) with the highest rate of LOH being observed at D9S171 on 9p13 (20%). Chromosome 9p LOH was associated with short tumor-specific survival in stage pT3 RCC (P = 0.01). Fluorescence in situ hybridization analysis of 54 CRCCs revealed no homozygous CDKN2A deletions indicating that this mechanism of CDKN2A inactivation is rare in CRCC. Sequencing of 113 CRCCs showed that 13 tumors (12%) had a 24-bp deletion abrogating codons 4 through 11 of CDKN2A. Immunohistochemical CDKN2A expression was absent in normal renal tissue and was only detected in six of 382 CRCCs (1.5%) on a renal tumor microarray. These data suggest that CDKN2A alterations are present in a small subset of CRCCs and a second, yet unknown tumor suppressor gene proximal to the CDKN2A locus, may play a role in CRCC development.
This article has been cited by other articles:
 |
|
 |
|
  R Natrajan, W Warren, B Messahel, J S Reis-Filho, M-A Brundler, J S Dome, P E Grundy, G Vujanic, K Pritchard-Jones, and C Jones Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours J. Clin. Pathol., January 1, 2008; 61(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Jones, J. N. Eble, M. Wang, G. T. MacLennan, B. Delahunt, M. Brunelli, G. Martignoni, A. Lopez-Beltran, S. M. Bonsib, T. M. Ulbright, et al. Molecular Genetic Evidence for the Independent Origin of Multifocal Papillary Tumors in Patients with Papillary Renal Cell Carcinomas Clin. Cancer Res., October 15, 2005; 11(20): 7226 - 7233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gunawan, A. von Heydebreck, T. Fritsch, W. Huber, R.-H. Ringert, G. Jakse, and L. Fuzesi Cytogenetic and Morphologic Typing of 58 Papillary Renal Cell Carcinomas: Evidence for a Cytogenetic Evolution of Type 2 from Type 1 Tumors Cancer Res., October 1, 2003; 63(19): 6200 - 6205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schraml, A. Hergovitz, F. Hatz, M. B. Amin, S. D. Lim, W. Krek, M. J. Mihatsch, and H. Moch Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression Am. J. Pathol., September 1, 2003; 163(3): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
